EMA shortages Shortage ongoing Medicine shortages
Risperidone — supply shortage (shortage ongoing)
Published by European Medicines Agency:
Summary
Supply shortage
Medicine
Risperidone
- Category
- Medicine shortages
- Product type
- Human medicine
- Active substance (INN): risperidone
- Therapeutic area: Schizophrenia
- Pharmaceutical forms affected: Prolonged-release suspension for injection
- Expected resolution: Risperdal Consta - by the end of 2025; Risperidone Teva and Sperizak - to continue until the end of 2026 or beginning of 2027
Measures and alternatives
- Availability of alternatives: Yes
Source: EMA — medicine shortages — European Medicines Agency
Source: European Medicines Agency (EMA). Reproduced with acknowledgement of the source, in line with the EMA legal notice. EU Safety Radar is an independent information service; the text above presents the official data in the original language — the notice published by the authority is authoritative.
Open the original notice (www.ema.europa.eu) ↗